nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

10.09.2017 | Original Article

Visualization of multiple organ amyloid involvement in systemic amyloidosis using ¹¹C-PiB PET imaging

verfasst von: Naoki Ezawa, Nagaaki Katoh, Kazuhiro Oguchi, Tsuneaki Yoshinaga, Masahide Yazaki, Yoshiki Sekijima

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the utility of Pittsburgh compound B (PiB) positron emission tomography (PET) imaging for evaluating whole-body amyloid involvement in patients with systemic amyloidosis.

Methods

Whole-body ¹¹C-PiB PET was performed in seven patients with systemic immunoglobulin light-chain (AL) amyloidosis, seven patients with hereditary transthyretin (ATTRm) amyloidosis, one asymptomatic TTR mutation carrier and three healthy controls. The correlations between clinical organ involvement, radiological ¹¹C-PiB uptake and histopathological findings were analysed for each organ.

Results

Organ involvement on ¹¹C-PiB PET imaging showed good correlations with the clinical findings for the heart and stomach. Abnormal tracer uptake was also observed in the spleen, lachrymal gland, submandibular gland, sublingual gland, lymph node, brain, scalp, extraocular muscles, nasal mucosa, pharynx, tongue and nuchal muscles, most of which were asymptomatic. Physiological tracer uptake was universally observed in the urinary tract (kidney, renal pelvis, ureter and bladder) and enterohepatic circulatory system (liver, gallbladder, bile duct and small intestine) in all participants. Most of the patients and one healthy control subject showed asymptomatic tracer uptake in the lung and parotid gland. The peripheral nervous system did not show any tracer uptake even in patients with apparent peripheral neuropathy. Histological amyloid deposition was confirmed in biopsied myocardium and gastric mucosa where abnormal ¹¹C-PiB retention was observed.

Conclusions

¹¹C-PiB PET imaging can be used clinically in the systemic evaluation of amyloid distribution in patients with AL and ATTRm amyloidosis. Quantitative analysis of ¹¹C-PiB PET images may be useful in therapy evaluation and will reveal whether amyloid clearance is correlated with clinical response.

Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40:104–14. https://doi.org/10.1007/s00259-012-2237-2.CrossRefPubMed

Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229–34. https://doi.org/10.1002/ana.21164.CrossRefPubMed

LeVine H III. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274–84.CrossRefPubMed

Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–20. https://doi.org/10.2967/jnumed.111.102053.CrossRefPubMed

Hellstrom-Lindahl E, Westermark P, Antoni G, Estrada S. In vitro binding of [3H]PIB to human amyloid deposits of different types. Amyloid. 2014;21:21–7. https://doi.org/10.3109/13506129.2013.860895.CrossRefPubMed

Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773–81. https://doi.org/10.1212/wnl.0000000000003001.CrossRefPubMed

Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004, 18-22 April 2004. Am J Hematol. 2005;79:319–28. https://doi.org/10.1002/ajh.20381.

Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785–91. https://doi.org/10.1016/j.humpath.2011.03.004.CrossRefPubMed

Scheinin NM, Tolvanen TK, Wilson IA, Arponen EM, Nagren KA, Rinne JO. Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PIB in humans. J Nucl Med. 2007;48:128–33.PubMed

10.

Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508–13. https://doi.org/10.1056/nejm199008233230803.CrossRefPubMed

11.

Rydh A, Suhr O, Hietala SO, Ahlstrom KR, Pepys MB, Hawkins PN. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur J Nucl Med. 1998;25:709–13.CrossRefPubMed

12.

Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, et al. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet. 1991;338:335–9.CrossRefPubMed

13.

Rowczenio D, Dogan A, Theis JD, Vrana JA, Lachmann HJ, Wechalekar AD, et al. Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol. 2011;179:1978–87. https://doi.org/10.1016/j.ajpath.2011.06.024.CrossRefPubMedPubMedCentral

14.

Hutt DF, Gilbertson J, Quigley AM, Wechalekar AD. (99m)Tc-DPD scintigraphy as a novel imaging modality for identification of skeletal muscle amyloid deposition in light-chain amyloidosis. Amyloid. 2016;23:134–5. https://doi.org/10.3109/13506129.2016.1158160.CrossRefPubMed

15.

Puille M, Altland K, Linke RP, Steen-Muller MK, Kiett R, Steiner D, et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med Mol Imaging. 2002;29:376–9.CrossRefPubMed

16.

Quarta CC, Obici L, Guidalotti PL, Pieroni M, Longhi S, Perlini S, et al. High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid. 2013;20:48–51. https://doi.org/10.3109/13506129.2012.746938.CrossRefPubMed

17.

Rao BK, Padmalatha C, Au Buchon J, Lieberman LM. Hepatic and splenic scintigraphy in idiopathic systemic amyloidosis. Eur J Nucl Med. 1981;6:143–6.CrossRefPubMed

18.

Janssen S, Piers DA, van Rijswijk MH, Meijer S, Mandema E. Soft-tissue uptake of 99mTc-diphosphonate and 99mTc-pyrophosphate in amyloidosis. Eur J Nucl Med. 1990;16:663–70.CrossRefPubMed

19.

Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195–201. https://doi.org/10.1161/circimaging.112.000132.CrossRefPubMedPubMedCentral

20.

Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23:58–63. https://doi.org/10.3109/13506129.2015.1135792.CrossRefPubMed

21.

Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652–62. https://doi.org/10.1007/s00259-014-2787-6.CrossRefPubMed

22.

Osborne DR, Acuff SN, Stuckey A, Wall JS. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir. Front Cardiovasc Med. 2015;2:23. https://doi.org/10.3389/fcvm.2015.00023.CrossRefPubMedPubMedCentral

23.

Broski SM, Spinner RJ, Howe BM, Dispenzieri A, Johnson GB. 18F-Florbetapir and 18F-FDG PET/CT in systemic immunoglobulin light chain amyloidosis involving the peripheral nerves. Clin Nucl Med. 2016;41:e115–7. https://doi.org/10.1097/rlu.0000000000000947.CrossRefPubMed

24.

García-González P, Sánchez-Jurado R, Cozar-Santiago MP, Ferrando-Beltrán M, Pérez-Rodriguez PL, Ferrer-Rebolleda J. Laryngeal and cardiac amyloidosis diagnosed by 18F-Florbetapir PET/CT. Rev Esp Med Nucl Imagen Mol. 2017;36:135–6. https://doi.org/10.1016/j.remn.2016.03.006.PubMed

25.

Leung N, Ramirez-Alvarado M, Nasr SH, Kemp BJ, Johnson GB. Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir. Br J Haematol. 2017;177:12. https://doi.org/10.1111/bjh.14519.CrossRefPubMed

26.

D'Estanque E, Chambert B, Moranne O, Kotzki PO, Boudousq V. 18F-Florbetaben: a new tool for amyloidosis staging? Clin Nucl Med. 2017;42:50–3. https://doi.org/10.1097/rlu.0000000000001434.CrossRefPubMed

27.

Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med. 1995;22:1393–401.CrossRefPubMed

28.

Schaadt BK, Hendel HW, Gimsing P, Jonsson V, Pedersen H, Hesse B. 99mTc-aprotinin scintigraphy in amyloidosis. J Nucl Med. 2003;44:177–83.PubMed

29.

Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med. 1995;22:595–9.CrossRefPubMed

30.

Bokhari S, Shahzad R, Castano A, Maurer MS. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014;21:175–84. https://doi.org/10.1007/s12350-013-9803-2.CrossRefPubMedPubMedCentral

31.

Ohyama T, Shimokama T, Yoshikawa Y, Watanabe T. Splenic amyloidosis: correlations between chemical types of amyloid protein and morphological features. Mod Pathol. 1990;3:419–22.PubMed

32.

Martins AC, Rosa AM, Costa E, Tavares C, Quadrado MJ, Murta JN. Ocular manifestations and therapeutic options in patients with familial amyloid polyneuropathy: a systematic review. Biomed Res Int. 2015;2015:282405. https://doi.org/10.1155/2015/282405.PubMedPubMedCentral

33.

Hachulla E, Janin A, Flipo RM, Saile R, Facon T, Bataille D, et al. Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum. 1993;36:691–7.CrossRefPubMed

34.

de Paula EF, de Mello BL, de Carvalho DL, Della-Guardia B, de Almeida MD, Marins LV, et al. Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy. Neurol Sci. 2017;38:311–8. https://doi.org/10.1007/s10072-016-2760-1.CrossRef

35.

Villa F, Dionigi G, Tanda ML, Rovera F, Boni L. Amyloid goiter. Int J Surg. 2008;6(Suppl 1):S16–8. https://doi.org/10.1016/j.ijsu.2008.12.025.CrossRefPubMed

36.

Matsuda M, Gono T, Shimojima Y, Yoshida T, Katoh N, Hoshii Y, et al. AL amyloidosis manifesting as systemic lymphadenopathy. Amyloid. 2008;15:117–24. https://doi.org/10.1080/13506120802006047.CrossRefPubMed

37.

Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59.PubMed

38.

Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med. 2014;53:403–12.CrossRefPubMed

Titel: Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging
verfasst von: Naoki Ezawa
Nagaaki Katoh
Kazuhiro Oguchi
Tsuneaki Yoshinaga
Masahide Yazaki
Yoshiki Sekijima
Publikationsdatum: 10.09.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2018
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3814-1

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Visualization of multiple organ amyloid involvement in systemic amyloidosis using ¹¹C-PiB PET imaging

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer

Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study

Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue

Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT

Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab